Publications

Sophia Shalhout, Romi Bloom, Lynn Drake, David Michael Miller (2020). Evaluation of the fragility of pivotal trials used to support FDA approval for plaque psoriasis.

Project Source Document DOI

Sophia Shalhout, Myrna R. Nahas, Reed E. Drews, David Michael Miller (2020). Generalized Acquired Cutis Laxa Associated with Monoclonal Gammopathy of Dermatological Significance.

Source Document

Melms, J. C., Vallabhaneni, S., Mills, C. E., Yapp, C., Chen, J. Y., Morelli, E., Waszyk, P., Kumar, S., Deming, D., Moret, N., Rodriguez, S., Subramanian, K., Rogava, M., Cartwright, A. N. R., Luoma, A., Mei, S., Brinker, T. J., David Michael Miller, Spektor, A., Schadendorf, D., Riggi, N., Wucherpfennig, K. W., Sorger, P. K., Izar, B., David Michael Miller (2019). Inhibition of Haspin kinase promotes cell-intrinsic and extrinsic anti-tumor activity.

Source Document

Klebanov, Nikolai, Gunasekera, Nicole S, Lin, William M, Hawryluk, Elena B, David Michael Miller, Reddy, Bobby Y, Christman, Mitalee P, Beaulieu, Derek, Rajadurai, Suvithan, Duncan, Lyn M, Sober, Arthur J, Tsao, Hensin (2019). Clinical spectrum of cutaneous melanoma morphology..

Source Document

David Michael Miller, Trowbridge, R. M., Desai, A., Drews, R. E. (2018). Eczema Tvecium.

Source Document Follow

Eliades, P., Abraham, B. J., Ji, Z., David Michael Miller, Christensen, C. L., Kwiatkowski, N., Kumar, R., Njauw, C. N., Taylor, M., Miao, B., Zhang, T., Wong, K. K., Gray, N. S., Young, R. A., Tsao, H. (2018). Role of CDK7 in Melanoma.

Source Document Follow

David Michael Miller, Faulkner-Jones, B. E., Stone, J. R., Drews, R. E. (2017). A Complete Response in cSCC with Ipi/Nivo.

Source Document Follow

Bobby Reddy, David Michael Miller, Hensin Tsao (2017). Somatic Driver Mutations in Melanoma.

Source Document

David Michael Miller (2016). A novel multi-CDK inhibitor in Melanoma.

Source Document

David Michael Miller (2016). Molecularly Targeted Therapies and Immunotherapies For Melanoma.

Source Document

David Michael Miller (2016). CDKs as Therapeutic Targets in Melanoma.

Source Document

David Michael Miller (2016). Molecular testing in melanoma.

Source Document

David Michael Miller (2010). Parameters for Establishing Humanized Mouse Models.

Source Document

David Michael Miller (2008). TLR Activation Abrogates Mixed Chimerism.

Source Document

David Michael Miller (2008). Viral infection - a potent barrier to transplantation tolerance.

Source Document

David Michael Miller (2008). TLR Agonists Abrogate Immunological Tolerance.

Source Document

David Michael Miller (2008). Role of Innate Immunity in Transplantation Tolerance.

Source Document

David Michael Miller (2007). Different mechanisms control peripheral and central tolerance.

Source Document

David Michael Miller (2004). Jellypin - a lower eukaryotic serine proteinase inhibitor (serpin).

Source Document

David Michael Miller (2002). The Serpin SQN-5.

Source Document